139 Participants Needed

AXS-05 for Alzheimer's Disease Agitation

Recruiting at 16 trial locations
Age: 65+
Sex: Any
Trial Phase: Phase 3
Sponsor: Axsome Therapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you must stop taking your current medications, but if you started a new medication since enrolling in the previous studies, it might be a concern if it poses a safety risk with AXS-05.

What data supports the effectiveness of the drug AXS-05 for Alzheimer's Disease Agitation?

AXS-05, a combination of dextromethorphan and bupropion, has been shown to be effective in treating major depressive disorder, with significant improvements in depression scores and high remission rates. While this data is for depression, it suggests potential benefits for Alzheimer's-related agitation due to the drug's impact on brain signaling.12345

Is AXS-05 (Dextromethorphan-Bupropion) safe for humans?

AXS-05, also known as Auvelity, has been approved for treating major depressive disorder in adults. It may increase the risk of suicidal thoughts in young people and can cause seizures, especially at higher doses. Common side effects include dizziness, nausea, headache, and dry mouth.12367

What makes the drug AXS-05 unique for treating agitation in Alzheimer's disease?

AXS-05 is unique because it combines dextromethorphan, which affects brain receptors involved in mood and behavior, with bupropion, which helps increase the effectiveness of dextromethorphan. Unlike other treatments, it is being investigated specifically for Alzheimer's-related agitation, and there are currently no FDA-approved drugs for this condition.12389

What is the purpose of this trial?

The primary objective of this open-label extension trial is to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 and ACCORD-2.

Eligibility Criteria

This trial is for individuals who have Alzheimer's disease with symptoms of agitation and participated in previous ADVANCE-2 or ACCORD-2 studies. It aims to understand the long-term safety of AXS-05, a medication intended to manage these symptoms.

Inclusion Criteria

Completed the treatment period in Study AXS-05-AD-304 or exited from Study AXS-05-AD-303 due to study completion
My caregiver agrees to follow the study's requirements and help me with my treatment.

Exclusion Criteria

I am currently living in a mental health facility, nursing home, or by myself.
Caregiver is unwilling or unable, in the opinion of the Investigator, to comply with study instructions
Any concurrent medical condition that might interfere with the conduct of the study, confound the interpretation of study results, or endanger the subject's well-being
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive AXS-05 for the treatment of Alzheimer's disease agitation

25 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Open-label extension

Participants may opt into continuation of treatment long-term

Long-term

Treatment Details

Interventions

  • AXS-05
Trial Overview The study tests the ongoing safety of AXS-05 (a combination of dextromethorphan and bupropion) in managing agitation associated with Alzheimer's over an extended period. This open-label trial allows all participants to receive the drug.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Open-LabelExperimental Treatment1 Intervention
Experimental: AXS-05 (dextromethorphan-bupropion) up to 25 weeks

AXS-05 is already approved in United States for the following indications:

🇺🇸
Approved in United States as Auvelity for:
  • Major depressive disorder

Find a Clinic Near You

Who Is Running the Clinical Trial?

Axsome Therapeutics, Inc.

Lead Sponsor

Trials
34
Recruited
11,600+

Findings from Research

Dextromethorphan/bupropion, a fixed-dose combination medication, was approved in August 2022 for treating major depressive disorder (MDD) in adults, highlighting its efficacy as a new treatment option.
The combination works by utilizing dextromethorphan as an NMDA receptor antagonist and sigma-1 receptor agonist, while bupropion enhances the bioavailability of dextromethorphan, potentially improving therapeutic outcomes.
Dextromethorphan/Bupropion: First Approval.Keam, SJ.[2022]
In a phase 3 trial involving 327 patients with major depressive disorder, AXS-05 (dextromethorphan-bupropion) significantly improved depressive symptoms compared to placebo, with effects noticeable as early as week 1.
The treatment led to a remission rate of 39.5% compared to 17.3% for placebo, and was generally well tolerated, with no serious side effects like weight gain or increased sexual dysfunction reported.
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).Iosifescu, DV., Jones, A., O'Gorman, C., et al.[2022]
In a phase 2 trial involving 80 patients with major depressive disorder, dextromethorphan-bupropion (AXS-05) showed a significantly greater reduction in depression symptoms compared to bupropion, with a mean change in MADRS score of -13.7 points versus -8.8 points over 6 weeks.
Dextromethorphan-bupropion also resulted in higher remission rates (46.5% vs. 16.2% at week 6) and response rates (60.5% vs. 40.5% at week 6), while being generally well tolerated with minimal adverse effects.
Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.Tabuteau, H., Jones, A., Anderson, A., et al.[2022]

References

Dextromethorphan/Bupropion: First Approval. [2022]
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). [2022]
Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. [2022]
Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. [2023]
R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. [2022]
New Combination Drug for Depression. [2023]
When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram. [2022]
AXS-05: an investigational treatment for Alzheimer's disease-associated agitation. [2022]
Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security